Rystiggo receives FDA approval, strengthening UCB’s myasthenia gravis portfolio
Pharmaceutical Technology,
Generalised myasthenia gravis is a rare condition – but UCB’s Rystiggo enters a competitive market.
Generalised myasthenia gravis is a rare condition – but UCB’s Rystiggo enters a competitive market.
Biologic License Application (BLA) designated Priority Review by FDA and seeks approval for rozanolixizumab for the treatment…
News provided by UCB Jan 06, 2023, 7:00 AM ET Biologic License Application (BLA) designated Priority Review by FDA and seeks…
Biologic License Application (BLA) designated Priority Review by FDA and seeks approval for rozanolixizumab for the treatment…